Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers

9 Feb 2018Oncotarget

DOI : 10.18632/oncotarget.24188

Authors

Luc Cabel, Alina Fuerea, Ludovic Lacroix, Capucine Baldini, Patricia Martin, Antoine Hollebecque, Sophie Postel-Vinay, Andrea Varga, Rastilav Balheda, Anas Gazzah, Jean-Marie Michot, Aurélien Marabelle, Etienne Rouleau, Eric Solary, Thierry De Baere, Eric Angevin, Jean-Pierre Armand, Stefan Michiels, Jean Yves Scoazec, Samy Ammari, Fabrice André, Jean-Charles Soria, Christophe Massard, Loic Verlingue

Members

PASCAL MARTIN

Directeur de recherche CNRS